Search

IU technologies to be promoted to biotech, pharma executives at 2016 BIO International Convention

  • June 3, 2016

FOR IMMEDIATE RELEASE

INDIANAPOLIS -- Technologies discovered and developed by Indiana University researchers will be promoted to biotechnology and pharmaceutical executives June 6 through 9 at the 2016 BIO International Convention in San Francisco.

Jennifer Finefield and Katherine Moynihan of the Indiana University Research and Technology Corp. will promote the technologies and build relationships within the biotechnology and pharmaceutical sectors at the conference. IURTC protects, markets and licenses intellectual property developed at Indiana University so it can be commercialized by industry.

Finefield, a senior technology manager, said the conference attracts thousands of leaders in the biotechnology and pharmaceutical sectors.

"We will network with more than 30 companies that have asked about Indiana University technology," she said. "We have also proactively targeted companies based on some of the outstanding technologies that we want to market. These networking meetings will increase the visibility of the IURTC technology portfolio."

Some IU technologies that will be promoted during networking meetings include:

Moynihan, an IURTC technology manager, said she and Finefield will also meet with consultants and venture capitalists at the event.

"These experts could strengthen companies developed through IURTC's Spin Up program, which helps IU researchers license and commercialize their work," she said. "Some of these attendees have funds to invest in that kind of company."

To request a meeting with Finefield or Moynihan at the 2016 BIO International Convention, email jfinefie@iu.edu or kmoyniha@iu.edu.

About the Indiana University Research and Technology Corp.

IURTC is a not-for-profit corporation tasked with the protecting and commercializing of technology emanating from innovations by IU researchers. Since 1997, IU research has generated more than 2,700 inventions resulting in over 3,900 global patent applications being filed by IURTC. These discoveries have generated $133 million in licensing and royalty income, including $111 million in funding for IU departments, labs and inventors.​